A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.

Inclusion Criteria: 1. First or second kidney transplant recipients, aged 18-75 years, PTH \> 150 pg/ml 2. De novo patients scheduled to receive ciclosporin A and prednisolone based immunosuppression. Exclusion Criteria: 1. Previous or current bone disease unrelated to end stage renal failure. 2. Patients with PTH \< 150pg/ml who may be at risk of adynamic bone disease. 3. Treatment at any time with a bisphosphonate. 4. d. Calcitonin treatment during the previous month. 5. Malignancy (current or history within last 5 years) 6. Pregnancy or lactation, or women of childbearing potential unwilling to use an effective form of contraception for the 12 month duration of the study. Protocol-defined inclusion/exclusion criteria may apply.